The chemical structure of drug molecules determines their fundamental pharmacological properties by 'fit' to the receptor, but the physicochemical properties, particularly lipid solubility and fraction un-ionised, dominate in determining distribution in the body and the rate of access to the biophase containing the drug receptors, For example, fentanyl appears much more potent than morphine because similar effective biophase concentrations are achieved with much smaller doses, Pharmacokinetic and pharmacodynamic investigations of the relationships between dose and the time-courses of blood concentrations and pharmacological effects of opioid drugs have helped explain the commonly observed variability between patients and have been useful in deriving effective dosage regimens of opioids such as pethidine, morphine, fentanyl and methadone where blood concentrations are a determinant of pharmacological response and 'target' analgetic blood opioid concentrations have been identifiable. However, there are instances when blood opioid concentrations are not determinants of the analgetic response. Examples include opioids, such as buprenorphine, for which the drug-receptor dissociation rate determines the duration of action, heroin which first has to be metabolised to become an agonist, pentazocine which is an agonist at some opioid receptors and an antagonist at others, and opioids placed intra-spina/ly acting on receptors in the spinal cord.
discussion of the structure-action relationships of opioids. This, however, was not a development of the period between the editions but was an area of intensive research of the 1920s and 1930s in an attempt to find a nonaddicting substitute for morphine in the way in which procaine had been developed as a substitute for cocaine several decades earlier.
The importance of chemical structure
Apart from the practicalities of selecting active compounds for clinical use from a variety of naturally occurring and synthetic derivatives, the importance of the chemical structures was not clear until the 1950s when Beckett and easy proposed that there must be a receptor for the opioids. J They suggested that a receptor was necessary to explain the common actions of compounds with chemical structures as diverse as morphine, methadone and pethidine. Moreover, like many other biologically active molecules, opioids also show a great degree of stereo-specificity so that one optical isomer may be an agonist but its enantiomorph may be inactive or even an antagonist. Thus, not only are the chemical groups on the molecule important but their arrangement in three-dimensional space is critical.
It is now well known that there is not a single opioid receptor but multiple receptors and that these respond to both the exogenous opioid agents and to endogenous opioids consisting of polypeptide molecules (e.g. enkephalins, endorphins, dynorphins and their derivatives). 4 These receptors are widely distributed in the body. They are responsible for different 'spectrums' of actions and they display preferences for rather than specificity to different exogenous as well as endogenous opioids. They respond in a dose-dependent manner when stimulated. 5 Thus by regulating the concentrations of opioids at these receptors a regulated response may be obtained. One means of regulating these concentrations, at least for exogenous opioids, lies in the choice of agent and the regimen for its administration.
Physicochemical properties of opioids
Since the 1960s, anaesthetists have become familiar with influences of physicochemical properties on the pharmacokinetic properties of inhalational agents. 6 Since the 1970s similar progress has been made for local anaesthetic agents. 7 However, such relationships have not been developed for the opioid agents, possibly due to a different emphasis being placed on the chemical properties of opioids. Development in structure-action relationships occurred before functional relationships were generally appreciated so that opioids traditionally have been classified chemically in relation to the morphine molecule. Chemical classifications into phenanthrenes, thebaines, phenylpiperidines, benzomorphans, etc. or alternatively into naturally occurring, synthetic or semi-synthetic classes became more widely used than the more useful functional descriptors such as lipid solubility and degree of ionisation.
For the majority of drugs, the chemical structure determines the access to and sojourn at the receptors (as well as the 'fit' on the receptor) through its effects on the functional or physicochemical properties of the drug. Therefore, the time course of the effects will be influenced by the physicochemical properties of the agent. For opioid drugs, the time course of effects of endogenous opioids should be considered as well. The limited data available suggest that the actions of exogenous and endogenous opioids are additive. 8 Unfortunately, there are insufficient data on the interaction of exogenous and endogenous opioids but there are sufficient data on which to examine the relationships between the physicochemical properties, pharmacokinetic properties and effects of exogenous mu-opioid receptor agonists. 4,5.9 
Influence of physicochemical properties on potency
One obvious difference between. the agents listed in Table 1 is the apparent potency. There is a five thousandfold difference in the typical intravenous dose required to produce equivalent analgesia in humans. This difference arises from a number of factors which are inextricably linked. After intravenous injection, the dose will be dispersed in the plasma volume, distributed to blood cells and other intravascular binding sites, distributed to tissues in accord with the distribution of cardiac output and tissue:blood partition coefficient, and diffuse into responsive tissues containing receptors. There the drug will combine with the receptors to elicit a biochemical and/or an electrical event and produce a pharmacological response. Hence, potency is affected by access to the receptors (i.e. the processes of distribution) as well as the fit of the agent onto the receptors (i.e. affinity constant in Table 2 ).
Regions containing receptors in the body have been collectively referred to as the 'biophase' and this distinguishes them from other drug binding or 'acceptor' sites. This terminology is generally applied in pharmacology, e.g. to the neuromuscular junction. Because opioid receptors are found in many heterogeneous tissues, it is not possible to define drug dose-or blood concentrationsresponse relationships for different receptor populations although binding affinities have been determined for different combinations of opioids and receptor types in vitr0 5 . 9 (Table 2) . At present, the most useful data for clinical purposes would seem to relate blood or plasma concentrations to global responses principally analgesia and respiratory depression, although data are emerging to correlate with anociception during anaesthesia. This is analogous to relating blood concentrations of muscle relaxants to degree of muscle paralysis. Although blood concentrations of opioids have been related to alterations in the EEG 10 and that this provides a convenient continuous signal by which central depressant agents may be examined, the relationship between this pharmacological effect and analgesia remains to be determined. In so far as receptor concentrations are in equilibrium with blood concentrations, all of these processes are affected by the global pharmacokinetic properties of the drug because these determine the blood concentrations and their time-course.
The physicochemical properties of pKa and lipid solubility I I are themselves related and these dominate other properties in determining the access of an agent to its receptors. The pKa value of a base is the negative logarithm of the dissociation constant of the ionised form (i.e. the cationic form or conjugate acid) of the molecule, and is functionally equal to the pH at which 50070 of the molecules <}re ionised. The cationic forms (existing in acidic pH) of the molecules are freely soluble in water but the base forms are virtually insoluble. Conversely, the base forms are lipid -rather than watersoluble. Thus at blood pH, the differences in pKa between the agents means that there will be a range in the fractions ionised and lipid solubilities (estimated by octanol:water partition coefficient in Table 1 ). Similarly, there will be a range of binding to plasma proteins and uptake by blood cells. The degree of binding increases with increasing fraction unionised indicating that hydrophobic bonding is involved. Although increasing the fraction unionised would also increase the ease of penetration of the blood cell membrane, no opioids are significantly concentrated in blood cells relative to the plasma.
Influence of pharmacokinetic properties on potency
In general, the apparent potency of the opioids correlates with the ease with which the unbound unionised lipid soluble portion in blood crosses the blood-brain barrier. This, for example, explains much of the difference in potency between morphine and fentanyl. A much greater fraction of a dose of fentanyl than that of morphine reaches the biophase and when this is allowed for, the agents have similar potency. 5, 9, 12 While the unbound unionised lipid soluble fraction of dose is potentially available to the receptors, the amount of drug reaching the receptors also will depend on the relative fractions of dose remaining in the blood and distributed to other tissues. Therefore, for opioids which penetrate membranes with ease, pharmacokinetic properties, particularly the apparent volumes of distribution which reflect tissue:blood partition coefficients, will become determinants of the response. In this context, apparent volume of distribution may be thought of as the volume into which one would have to dilute a given dose of the drug in order to obtain the blood concentration in question. For example, differences in the degree of tissue uptake would seem to explain differences between fentanyl and alfentanil ( Table 2 ). The onset and offset of action of alfentanil are both more rapid than those of fentanyl: fentanyl has a larger 'volume' to 'fill' and takes longer to do it, i.e. there is a longer equilibration delay with fentanyl. \0 This is analogous to the difference between nitrous oxide and halothane.
Biophase and receptor kinetics
In all receptor-mediated drug responses, drug continually associates with and dissociates from receptor due to continuous bombardment of the drug-receptor complex with water and solute molecules. Not all opioid-receptor bonds are made or broken at the same rates, but rather these rates are functions of the relative association-dissociation constants of the particular drugs and populations of receptors, so that the times to reach equilibrium may differ between drugs. 5 ,13 The physicochemical properties seem to exert dual but paradoxical actions on the central actions of opioids. While high lipid solubility and an abundance of unionised drug may assist the passage of the drugs across the blood brain barrier (e.g. compare morphine and fentanyl), it also seems to confer slow receptor kinetics upon opioids. This may be because penetration of a hydrophilic barrier is required before the conjugate acid of the opioid can occupy an anionic site on the receptor.
Differences in receptor kinetics among pure mu receptor agonist opioids in clinical use appear to be small so that their time-effect Anaesthesia and jnrensi}'e Care, Vol. 15 . No. 1. February, 1987 relationships are dominated by the global kinetics which determine blood concentrations. However, for the partial mu receptor agonist buprenorphine and for the agonistlantagonisttype drugs, the kinetics of the analgesic response appear to be dominated by the kinetics of dissociation from the receptor. This is much slower for buphrenorphine than for fentanyl. 13 The consequence of this is that blood concentrations and pharmacokinetic profiles 14 are not very useful in designing dosage regimens of drug but are useful for making inferences about absorption of bioavailability.
Global pharmacokinetic properties
As described elsewhere, drugs can be characterised by their distribution volumes which may be derived in several different ways and by their clearances, irrespective of the application of compartment or other pharmacokinetic models to describe their behaviour. Is Their half-lives emerge as derived values from these primary variables. Models are useful in this context because they provide convenient summary data on which to compare drugs or predict their behaviour. Each drug has an initial dilution volume which relates the blood concentrations to dose immediately after an intravenous dose (and which may differ appreciably between arterial and venous blood) but these do not seem to differ much between opioid agents studied under the same conditions. There is also a total apparent distribution volume which describes the relationship between blood concentration and body content of drug at equilibrium. This may differ slightly according to the method of allowing for drug elimination in the calculation. The ratio of the latter volume to the former gives an index of the degree of tissue affinity for the drug. Plainly, the larger the volume of distribution, then the smaller the blood concentration from a given dose. Initial dilution volumes in Table 2 are derived from arterial blood concentration data. These, like values for 'distribution half-lives', are influenced more by choice of experimental conditions and patient (especially haemodynamic) variables than by choice of drug. Therefore the values listed in Table 2 should be regarded only as approximate since they were derived from a variety of reports using different experimental conditions. Anaesthesia and Intensive Care, Vol. 15. No. I. February, 1987 Distribution half-lives bear no physiological reality. They exist only to describe the rate of change of blood concentrations before equilibrium exists between drug concentrations in blood and tissues. At least one 'distribution phase' is commonly resolved in a set of blood concentration-time data. However, mixing may be so rapid that the distribution phase is not obvious or it may be slower so that two phases or more are clearly visible. The 'distribution half-lives' for all of the opioids range from several minutes to nearly one-half hour. Any real (rather than experimental) differences between drugs are probably explicable in terms of tissue solubilities and physicochemical properties. It is unimportant how many 'compartments' seem to be 'required' for a particular drug in a particular individual. These represent an attempt to rationalise a complicated physiological problem with a relatively simple statistical solution. Plainly, there is an infinite number of real compartments and these should not be confused with a model of the drug's behaviour.
Clearance may be defined as the volume of blood or plasma from which drug is completely removed per unit time. In fact the full flow of blood to each organ is only partially cleared of drug. The measure of efficiency of drug elimination by each organ or tissue then equals the product of organ or tissue blood flow and extraction ratio. Total body clearance equals the sum of clearances by all pathways of elimination, i.e. metabolism plus excretion, and is the determinant of the average blood concentration at steady state. In humans, the mean total body clearance is usually determined and this is calculated from the Fick principle as being equal to the dose/total area under the blood concentration-time curve. A high total clearance means frequent doses will be required to maintain a particular blood concentration. Of the opioids listed in Table 2 , fentanyl, morphine, pentazocine, nalbuphine, butorphanol and buprenorphine may be regarded as having high clearances; pethidine, sufentanil and alfentanil as having intermediate clearances; methadone as having a low clearance. But, as noted above, the relationship between blood concentrations and analgesic response is unclear for partial agonists and the agonist/antagonist opioids.
In humans, clearance of opioids by organs other than the liver is generally insignificant. Some investigators have claimed that renal dysfunction influences the total body clearance of opioids [15] [16] [17] [18] and have suggested this is indirect evidence for the renal metabolism of morphine and its congeners although others have disputed this. 19 It is plain that further investigation of the interaction of opioids and the kidney are urgently required. There is no doubt, however, that hepatic clearance is the principal determinant of oral bioavailability. The latter can be approximated by the equation:
Oral Bioavailability = 1 -(clearance/hepatic blood flow) It is probable that the duration of action of single doses of opioids administered intravenously are more influenced by redistribution of drug from blood to tissues than by metabolism. Metabolism, and therefore clearance, undoubtedly is more important on continuous or repeated dosing. The elimination half-life reflects the ratio of total distribution volume to clearance. In general, opioids are metabolised to analgesically less active derivatives. There are, however, some notable exceptions. Heroin does not bind effectively to opioid receptors in vitro 20 and it is believed that successive metabolism to mono acetyl morphine and morphine is responsible for the analgesic action of heroin. Similarly, at least part of the analgesia from codeine is produced through partial metabolism to morphine. In those cases where a drug has active metabolites, accurate determination of a target blood concentration for a predictable response becomes extremely difficult. [20] [21] [22] [23] [24] [25] 
Variations in pharamacokinetic properties
The pharmacokinetic properties of opioids can be affected by the extremes of age, disease states and the administration of other drugs but there are few quantitative data about the effects on pharmacodynamic properties. 22 -25 Of all the opioids, pethidine has been studied the most but generalisations may be expected to apply to other agents as well since they are mainly cleared by metabolism. In human neonates, the elimination half-life of pethidine is seven times greater than in adults. Thus, the newborn whose mothers have received opioids in labour may need several doses of naloxone and exhibit neurobehavioural differences for several days. It is not an issue for breast-feeding mothers since transmission via milk is negligible, although measurable. In geriatric patients, the distribution of pethidine is smaller and its clearance is lower -both factors giving higher blood concentrations per dose. Thus, there are sound pharmacokinetic reasons for the clinical observation that the elderly may need smaller doses of opioids than younger patients.
Liver disease (cirrhosis, hepatitis) reduces the clearance of pethidine and prolongs its half-life without altering its distribution. Thus, the initial dose need not be changed but subsequent doses administered at the same frequency need to be smaller. If doses of the same size are administered at longer intervals, high peak blood concentrations increase the possibility of adverse effects. If dose escalation is required in patients with malignant disease, on the limited data available it seems that this is not due to changes in pharmacokinetic parameters such as increased rates of metabolism. Concomitant administration of phenytoin, which induces hepatic enzymes, increases the clearance of pethidine by up to 25070, thus shortening its half-life. Conversely, cimetidine (but not ranitidine) administration may reduce the clearance of pethidine by dual effects on hepatic blood flow and hepatic metabolism. Cimetidine does not alter morphine clearance in humans.
The pharmacokinetic properties in Table 2 are a useful basis for the comparison of opioids and the design of dosage regimens or intravenous infusions if the. target blood concentrations can be identified. It was not apparent until recently that blood concentrations associated with analgesia could be identified, although there remains considerable room for investigation. 18 ,22 The general philosophy of determining target concentrations and designing intravenous infusions has been given elsewhere in this issue but it should be noted that the most useful opioids for infusion will have either a high total body clearance (e,g. fentanyl), a small total volume of distribution (e.g. alfentanil), or both (e.g. morphine). Agents with low clearance like methadone do not require intravenous infusion.
Absorption and minimum effective blood concentrations of opioids
A fourfold variability in minimum effective blood concentrations of opioids among individual patients is commonly reported in studies where the drug is given intravenously. Apart from any variability in endogenous opioids, variable pain control with intramuscular opioids is due also to the variable (and uncontrollable) rates of systemic absorption which are common in this route of administration. These are not reproducible even in successive injections in the same patient because it is not possible to place the drug precisely in the same region every time. Local differences in perfusion control the rate of absorption so that differences in fat-lean tissue mass at the injection site will result in different blood concentrations being attained. 21 ,24.26 Studies of multiple injections of pethidine have shown that the maximum blood concentration after standardised gluteal injections may occur from 10 minutes to 90 minutes accompanied by a fourfold variation in the maximum blood concentrations. Hence, some patients achieve analgesia only briefly between doses.
Absorption after oral administration of opioids is variable and complex because of the physiological vagaries~of this route (food, pH, etc.) but it is the hepatic 'first pass' clearance which dominates the bioavailability part of the kinetic profile. Other routes of enteral administration which reduce the degree of first pass extraction by the liver and are suitable for opioids include sublingual, buccal and rectal. Sublingual administration has been reported as very successful in the postoperative treatment of pain with buprenorphine. The sublingual route may be slow to build effective concentration and may require a parenteral priming dose. Buccal application of morphine and the rectal application of many opioids, including morphine, pethidine and pentazocine, have been shown to be effective, although of slower absorption rate than other common routes. The rectal route may be effective in providing analgesia of longer duration than usual and is suitable for nighttime administration.
Absorption after epidural injections resembles the absorption after intramuscular injections and can contribute to the systemic Anaesthesia and Intensive Care, Vol. 15, No. /, February, 1987 effects of the opioid over a similar time-course. However, the principal action is due to opioid which is not systemically absorbed but partitions into cerebrospinal fluid, spinal cord and then to its receptors. This, ultimately, is the source of analgesic actions and unfortunately of late onset respiratory depression. 27 
Some conclusions
While it is possible to design and build a 'better morphine'28 which may have a different time course in the blood, at the receptors, or be recognised differently by the receptors, it is questionable as to whether it will be 'better' or just 'different'. With knowledge of the pharmacokinetics of the opioids in relation to their effects, much of the 'betterness' can be offset by recognising and making allowances for the differences.
